Contribute Try STAT+ Today

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of Zoom meetings, Skype calls, and deadlines has predictably returned. But what can you do? The world keeps spinning, after all. So time to give it a bit of a nudge with a delicious cup of stimulation. Our choice today is cinnamon mocha. Yum. Feel free to join us. Meanwhile, here are some tidbits to help you along. We hope your day is productive and free of stress. Meanwhile, stay safe — wear that mask. …

BioNTech (BNTX), which joined with Pfizer (PFE) to make the first Covid-19 vaccine in the West, is building a new manufacturing alliance that could throw Europe and the rest of the world a lifeline amid a painful shortage of shots and a rebound in infections, The Wall Street Journal writes. The company has marshaled an alliance of 13 companies, including Novartis (NVS),  Merck (MRK), and Sanofi (SNY), in an effort to meet — and perhaps exceed — an ambitious target of making 2 billion doses of vaccine this year.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.